Tscan Therapeutics Inc Cash Flow Conversion Efficiency
Tscan Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Tscan Therapeutics Inc (TCRX) has a cash flow conversion efficiency ratio of -0.399x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-27.54 Million) by net assets ($69.02 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Tscan Therapeutics Inc (2019–2025)
Cash flow conversion efficiency of Tscan Therapeutics Inc from 2019 to 2025. This chart illustrates how Tscan Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Tscan Therapeutics Inc (TCRX) stock price for real-time trading data and today's change.
Tscan Therapeutics Inc Cash Flow Conversion Ratio Explained
Tscan Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Tscan Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tscan Therapeutics Inc ranked by their cash flow conversion efficiency. Also see market cap of Tscan Therapeutics Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thunderbird Resources Ltd
AU:THB
|
-0.043x |
|
GreenOak Spain Holdings SOCIMI S.A.
MC:YGO2
|
N/A |
|
Aalborg Boldspilklub A/S
CO:AAB
|
-0.204x |
|
Gurktaler Aktiengesellschaft
VI:GAGV
|
N/A |
|
WIN Metals Ltd
AU:WIN
|
-0.183x |
|
Ben Tre Pharmaceutical JSC
VN:DBT
|
N/A |
|
Vroom, Inc.
NASDAQ:VRMMQ
|
0.715x |
|
Trailbreaker Resources Ltd
V:TBK
|
-0.011x |
Annual Cash Flow Conversion Efficiency for Tscan Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Tscan Therapeutics Inc from 2019 to 2025. Review TCRX FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $123.12 Million | $-135.32 Million | -1.099x | -138.98% |
| 2024-12-31 | $240.97 Million | $-110.82 Million | -0.460x | -13.08% |
| 2023-12-31 | $150.87 Million | $-61.36 Million | -0.407x | +39.19% |
| 2022-12-31 | $99.43 Million | $-66.50 Million | -0.669x | -120.91% |
| 2021-12-31 | $160.78 Million | $-48.68 Million | -0.303x | -525.26% |
| 2020-12-31 | $-42.46 Million | $-3.02 Million | 0.071x | +124.19% |
| 2019-12-31 | $42.54 Million | $-12.52 Million | -0.294x | -- |
About Tscan Therapeutics Inc
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic… Read more